BioinvestGPT

BioinvestGPT ApS · Research use only

NCT05089734 (Sacituzumab Govitecan-hziy Docetaxel in Non-Small Cell Lung Cancer): BVCT ex-ante prediction vs. reported outcome

On 5 Jan 2024, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 22 Jan 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT05089734
Acronym
EVOKE-01
Drug Name
Sacituzumab Govitecan-hziy (SG) Docetaxel
Drug MoA
anti-TROP2 ADC with SN38 payload for lysosomal-degradation-mediated intracellular release
Drug Modality
ADC
Drug Class
First-In-Class
Therapeutic Area
Neoplasms
Indication
Non-Small Cell Lung Cancer (NSCLC)
Human Patients
603
Sponsor
Gilead Sciences
Phase
Phase 3

Prediction of , index 1408

Prospective Prediction
Prediction Index
1408
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak additional clinical benefit in OS compared with docetaxel)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
17 days in advance
Readout Data Interpretation
OS primary endpoint not met.
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy
Phase
Phase 3
Status
Active not recruiting
Enrollment
603
Lead sponsor
Gilead Sciences
Conditions
Non-Small Cell Lung Cancer
Interventions
BIOLOGICAL: Sacituzumab Govitecan-hziy (SG); DRUG: Docetaxel
Design
Randomized · Parallel · None
Primary purpose
Treatment
Start
2021-11-17
Primary completion
2023-11-29
Completion
2027-01
Results first posted
2025-01-14
Primary outcomes
  • Overall Survival (OS) (Up to 24.4 months)

NCT05089734 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials